MYC and diffuse large B-cell lymphoma: Since reliable prognostic tools for DLBCL are insufficient, different instruments based either on clinically oriented parameters (e.g., IPI, NCCN-IPI), molecular classification (e.g., cell-of-origin) and even more advanced genetic markers (e.g., MYC/BCL2 rearrangements, DHITsig, MCD/EZB clusters), have been tested [1].